GT Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the annual meeting of stockholders held by GT Biopharma, Inc. on June 25, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol GTBP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
At the annual meeting, 1,380,633 shares were entitled to vote, with 691,084 shares (50.05%) represented. The following matters were approved:
- Proposal 1 (Election of Directors): Four directors were elected. Michael Breen and Rajesh Shrotriya, M.D. received over 90% of votes cast. Bruce Wendel received approximately 69% of votes cast, and Charles J. Casamento received approximately 80% of votes cast.
- Proposal 2 (Ratification of Accountants): The appointment of Weinberg & Company, P.A. as independent accountants was ratified with 579,726 votes for, 89,595 against, and 21,763 abstentions.
- Proposal 3 (Executive Compensation): The non-binding advisory vote on executive compensation passed with 277,591 votes for, 47,062 against, and 6,392 abstentions. There were 360,039 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented at the meeting (50.05%).
- Confirm the specific vote counts for Bruce Wendel, who received a lower percentage of "For" votes compared to other director nominees.
- Note the significant number of broker non-votes (360,039) on the executive compensation proposal.
- Confirm the tenure of the newly ratified independent accountants, Weinberg & Company, P.A.